Context Therapeutics Statistics
Total Valuation
CNTX has a market cap or net worth of $115.12 million. The enterprise value is $37.69 million.
Important Dates
The last earnings date was Wednesday, November 6, 2024, after market close.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CNTX has 75.00 million shares outstanding. The number of shares has increased by 162.59% in one year.
| Current Share Class | 75.00M |
| Shares Outstanding | 75.00M |
| Shares Change (YoY) | +162.59% |
| Shares Change (QoQ) | +46.44% |
| Owned by Insiders (%) | 1.45% |
| Owned by Institutions (%) | 29.79% |
| Float | 39.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.46 |
| P/TBV Ratio | 1.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 36.91, with a Debt / Equity ratio of 0.00.
| Current Ratio | 36.91 |
| Quick Ratio | 36.36 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -58.98% and return on invested capital (ROIC) is -39.70%.
| Return on Equity (ROE) | -58.98% |
| Return on Assets (ROA) | -37.22% |
| Return on Capital (ROIC) | -39.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$6.03M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +63.00% in the last 52 weeks. The beta is 2.25, so CNTX's price volatility has been higher than the market average.
| Beta (5Y) | 2.25 |
| 52-Week Price Change | +63.00% |
| 50-Day Moving Average | 2.02 |
| 200-Day Moving Average | 1.83 |
| Relative Strength Index (RSI) | 29.77 |
| Average Volume (20 Days) | 210,074 |
Short Selling Information
The latest short interest is 1.02 million, so 1.37% of the outstanding shares have been sold short.
| Short Interest | 1.02M |
| Short Previous Month | 1.03M |
| Short % of Shares Out | 1.37% |
| Short % of Float | 2.61% |
| Short Ratio (days to cover) | 2.79 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -32.55M |
| Pretax Income | -18.57M |
| Net Income | -30.15M |
| EBITDA | -32.54M |
| EBIT | -32.55M |
| Earnings Per Share (EPS) | -$0.72 |
Full Income StatementBalance Sheet
The company has $84.80 million in cash and $244,360 in debt, giving a net cash position of $84.56 million or $1.13 per share.
| Cash & Cash Equivalents | 84.80M |
| Total Debt | 244,360 |
| Net Cash | 84.56M |
| Net Cash Per Share | $1.13 |
| Equity (Book Value) | 83.86M |
| Book Value Per Share | 1.12 |
| Working Capital | 83.74M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$16.88 million and capital expenditures -$7,316, giving a free cash flow of -$16.88 million.
| Operating Cash Flow | -16.88M |
| Capital Expenditures | -7,316 |
| Free Cash Flow | -16.88M |
| FCF Per Share | -$0.23 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |